Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Authors :: Alan F. List
Jeffrey E. Lancet
Michaela Fontenay
Najla Al Ali
Chen Wang
Amy F McLemore
Olivier Kosmider
Rami S. Komrokji
Ashley A. Basiorka
Pierre Fenaux
Eric Padron
Kathy L. McGraw
David A. Sallman
Source :: Haematologica. 107:737-739
Publication Year :: 2021
Publisher :: Ferrata Storti Foundation (Haematologica), 2021.

Subjects :: business.industry
Myelodysplastic syndromes
Hematology
medicine.disease
Lower risk
Myelodysplastic Syndromes
medicine
Cancer research
Erythroid response
Chromosomes, Human, Pair 5
Humans
Chromosome Deletion
business
Recombinant erythropoietin
Erythropoietin
Lenalidomide
Biomarkers
medicine.drug

Full Text Access

Tools